Healthy Clinical Trial
Official title:
An Attempt at Translating Novelty-enhanced Extinction of Context Conditioning From Rodents to Humans
Verified date | June 2022 |
Source | Uppsala University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In rodents, novel exploration has been used to strengthen the consolidation of a variety of hippocampal-dependent learning tasks. To our knowledge, no attempt have been made to translate the effect of strengthening the memory of an extinction of a context conditioning memory. This study uses virtual reality for both context conditioning and novel exploration in an attempt at translating these findings from rodents to humans, thus, using novel exploration to strengthen an extinction memory. Threat responses are measured with skin conductance and startle responses. If this effect could be shown experimentally in humans, that experimental setup could become an important tool in understanding important memory processes of fear, such as reconsolidation and behavioral tagging.
Status | Completed |
Enrollment | 60 |
Est. completion date | May 1, 2022 |
Est. primary completion date | May 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Willing and able to provide informed consent and complete study procedures Exclusion Criteria: - Current psychiatric disorder. - Current use of psychotropic medication - Current use of neurological conditions |
Country | Name | City | State |
---|---|---|---|
Sweden | Uppsala University, deparmtent of Psychology | Uppsala |
Lead Sponsor | Collaborator |
---|---|
Uppsala University |
Sweden,
Moncada D, Ballarini F, Viola H. Behavioral Tagging: A Translation of the Synaptic Tagging and Capture Hypothesis. Neural Plast. 2015;2015:650780. doi: 10.1155/2015/650780. Epub 2015 Aug 25. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Navigation success | Questions designed to probe the amount of navigation performed by participants doing the novel exploration task. Three yes/no question of "Did you find object X?" and then participants are asked to point at their position in a stylized map overviewing the novel exploration context. | Day 2 | |
Other | State-Trait Anxiety Inventory (STAI-T) | This is a self-rated questionnaire measuring trait anxiety. Higher scores indicate higher level of trait-anxiety (range 20-80). | Day 2 | |
Other | Generalized anxiety disorder 7 (GAD-7) | This is a self-rated questionnaire for screening and severity measuring of generalized anxiety disorder (range 0-21). Higher scores indicate more symptoms of generalized anxiety. | Day 2 | |
Other | Patient Health Questionnaire 9 (PHQ-9) | This is a self-rated questionnaire for screening for the presence and severity of depression (0-27). Higher scores indicate a more symptoms, and severity of symptoms, of depression | Day 2 | |
Primary | Physiological arousal response during reinstatement. | Startle responses and skin conductance responses are used as measures of physiological arousal response. | Day 3 | |
Secondary | Physiological arousal response during extinction | Startle responses and skin conductance responses are used as measures of physiological arousal response | Day 2 | |
Secondary | Physiological arousal response during threat conditioning | Startle responses and skin conductance responses are used as measures of physiological arousal response | Day 1 | |
Secondary | Subjective fear ratings | Subjective ratings of fear (0-100) where 0 is no fear and 100 is worst imaginable fear. | Day 1, 2 & 3. | |
Secondary | Subjective discomfort ratings | Subjective ratings of discomfort where 0 is no discomfort and 100 is worst imaginable discomfort. | Day 1, 2 & 3 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |